Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H. Raffoux E, et al. Among authors: delarue r. J Clin Oncol. 2003 Jun 15;21(12):2326-34. doi: 10.1200/JCO.2003.01.149. J Clin Oncol. 2003. PMID: 12805334 Clinical Trial.
Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments.
Lepelletier Y, Camara-Clayette V, Jin H, Hermant A, Coulon S, Dussiot M, Arcos-Fajardo M, Baude C, Canionni D, Delarue R, Brousse N, Benaroch P, Benhamou M, Ribrag V, Monteiro RC, Moura IC, Hermine O. Lepelletier Y, et al. Among authors: delarue r. Cancer Res. 2007 Feb 1;67(3):1145-54. doi: 10.1158/0008-5472.CAN-06-1962. Cancer Res. 2007. PMID: 17283149
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G. Bachy E, et al. Among authors: delarue r. J Clin Oncol. 2010 Feb 10;28(5):822-9. doi: 10.1200/JCO.2009.22.7819. Epub 2009 Dec 21. J Clin Oncol. 2010. PMID: 20026809
Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives.
Chandesris MO, Malamut G, Verkarre V, Meresse B, Macintyre E, Delarue R, Rubio MT, Suarez F, Deau-Fischer B, Cerf-Bensussan N, Brousse N, Cellier C, Hermine O. Chandesris MO, et al. Among authors: delarue r. Gastroenterol Clin Biol. 2010 Nov;34(11):590-605. doi: 10.1016/j.gcb.2010.09.008. Epub 2010 Nov 2. Gastroenterol Clin Biol. 2010. PMID: 21050687 Free article. Review.
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Peyrade F, et al. Among authors: delarue r. Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7. Lancet Oncol. 2011. PMID: 21482186 Clinical Trial.
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquières H, Bouabdallah K, Morschhauser F, Coiffier B, Le Gouill S, Bologna S, Delarue R, Huynh A, Bosly A, Brière J, Gisselbrecht C. Decaudin D, et al. Among authors: delarue r. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):212-8. doi: 10.1016/j.clml.2011.03.007. Epub 2011 Apr 9. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21575926 Clinical Trial.
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Récher C, et al. Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4. Lancet. 2011. PMID: 22118442 Free article. Clinical Trial.
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.
Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, Delmer A, Salles G, Morschhauser F, Delarue R, Brice P, Bouabdallah R, Casasnovas O, Tilly H, Gaulard P, Haioun C. Delfau-Larue MH, et al. Among authors: delarue r. Haematologica. 2012 Oct;97(10):1594-602. doi: 10.3324/haematol.2011.061507. Epub 2012 Feb 27. Haematologica. 2012. PMID: 22371178 Free PMC article. Clinical Trial.
160 results